德琪医药(06996.HK) 公布,希维奥(塞利尼索片)的新适应症,用于治疗接受过至少两线系统性治疗的复发或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成年患者,已被纳入于明年1月1日起正式生效的2024年版国家医保药品目录(NRDL)。(sl/u)(港股报价延迟最少十五分钟。)
AASTOCKS新闻Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.